NCT06594159

A Study of LY4065967 in Healthy Japanese Participants

A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of LY4065967, to Evaluate the Effect of LY4065967 on the Pharmacokinetics of Rosuvastatin in Healthy Japanese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants. Blood tests will be performed to check how much LY4065967 and rosuvastatin get into the bloodstream and how long it takes the body to eliminate it. This is a 3-part study and will last approximately 2 weeks excluding screening period for each part.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY4065967	Administered orally
DRUG	Placebo	Administered orally
DRUG	Rosuvastatin	Administered orally

Timeline

• Start date: 2024-10-22
• Primary completion: 2025-03-11
• Completion: 2025-03-11
• First posted: 2024-09-19
• Last updated: 2025-04-03

Locations

1 site across 1 country: Japan